Bay Area Biotech Committed to Advancing Novel Therapies for Unmet Needs

Spruce Biosciences is a clinical-stage biopharmaceutical based in San Francisco, California. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). As a forward-thinking Bay Area biotech, we are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Spruce’s lead program is being developed to serve the chronic and acute needs of patients with Congenital Adrenal Hyperplasia.

Board of Directors + Investors +

Now Enrolling Patients for

Congenital Adrenal Hyperplasia Clinical Trials 2017

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new, once-a-day therapy for CAH. To be notified when a site opens near you, sign up for our mailing list.

Learn More

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.